World Federation of Neurology Research Group ALS/MND

January 2008

A NEW EDITOR FOR THE “BLACK BUT NOT BLEAK” JOURNAL: ALS RESEARCH IS COMING OF AGE

The Amytrophic Lateral Sclerosis journal, the official organ of the World Federation of Neurology (WFN) Research Group on ALS/MND, is having a mini-make over, reflecting the very real and exciting change in pace of ALS research . A new editor, Neurologist Prof. Orla Hardiman from Dublin, Ireland, has been appointed, and the newly invigorated Editorial Board drawn from across the world of ALS clinicians and scientists will provide regular in-depth reviews of “hot topics”, in addition to encouraging rapid dissemination of peer reviewed clinical, translational and basic science research of high quality.

The WFN Research Group facilitates collaboration across borders defined by both geography and discipline, and new members are always welcome to this important network. The ALS Journal is the only dedicated publication for this rapidly progressive neurodegenerative disease, and membership of the WFN members are automatic subscribers to the Journal.

“Working together as a community of clinicians, scientists and care providers, we must continue to strive to make a difference in the lives of people with ALS. As the incoming editor I, with the new editorial board, will do my best to attract and publish research that will help to make that difference a reality” said Orla Hardiman, incoming editor.

To find out more about the ALS Journal, and to become a subscriber, click on http://www.informaworld.com/als.
To find out more about the World Federation of Neurology Research Group on ALS/MND, click on http://www.wfnals.org

About ALS/MND
Amytrophic Lateral Sclerosis (ALS) / Motor Neurone Disease (MND) is a neurodegenerative condition that frequently affects people in the prime of their lives. The incidence of MND is approximately half that of Multiple Sclerosis – it is not a rare condition. Life expectancy ranges from 3 months to over 10 years from first symptoms. Although MND remains a fatal illness, a combination of disease modifying treatment and symptom control can improve the overall quality of life of patients. ALS/MND research is graced with some of the brightest and most talented researchers in clinical and basic science. New scientific collaborations across disciplines and continents will facilitate major scientific advances. These in turn will soon translate into new treatments that will slow, and eventually reverse this tragic condition

END

Main Navigation